Smartsheet (SMAR)
This work-management platform helps companies implement, organize and automate their processes. Smartsheet says its application is used by more than 80% of Fortune 500 companies.
And business is growing. In the fiscal quarter ended April 30, revenue surged 44% year over year to $168.3 million, driven by a 44% increase in subscription revenue.
Notably, Smartsheet’s dollar-based net retention rate was a solid 133%.
But the stock is far from being a hot commodity. Year to date, shares are down a painful 61%. That could give contrarian investors something to think about.
Last week, JPMorgan analyst Pinjalim Bora reiterated an “overweight” rating on Smartsheet. While Bora also lowered his price target from $80 to $58, the new target is still 96% above where the stock sits today.
With Qtrade Direct Investing™, you can build, evaluate and test your portfolio using analyst research and tools that feature their most advanced risk analysis and portfolio-building technology.
Now get up to $150 sign-up bonus until June 30, 2023 with promo code BONUS150.
Division of Credential Qtrade Securities Inc.
Get StartedMicrosoft (MSFT)
Tech stocks are getting dumped in this market downturn. Even mega-cap behemoths like Microsoft aren’t immune to the bearish sentiment.
The stock has tumbled 26% in 2022.
But business remains on the right track. In the March quarter, Microsoft’s revenue grew 18% year over year to $49.4 billion. Adjusted earnings came in at $2.22 per share, up 9% from the year-ago period.
The tech gorilla is also returning a massive amount of cash to investors. For the quarter, Microsoft’s dividends and share buybacks totaled $12.4 billion, representing a 25% increase year over year.
JPMorgan analyst Mark Murphy recently raised his price target on Microsoft to $320 while maintaining a “buy” rating. That implies a potential upside of 30%.
Eli Lilly (LLY)
This American pharmaceutical giant commands more than $270 billion in market cap, with products marketed in 120 countries around the world.
Unlike the other two names on this list, Eli Lilly is not a beaten-down stock.
In Q1, Eli Lilly delivered 15% revenue growth, driven by a 20% growth in volume. The company paid nearly $900 million in dividends and spent $1.5 billion on buybacks during the quarter.
Shares are actually up 7% so far in 2022, and JPMorgan expects the trend to continue.
On June 1, analyst Chris Schott reiterated an “overweight” rating on Eli Lilly while raising his price target from $340 to $355.
Considering that shares trade at around $291 apiece right now, the new price target implies a potential upside of 22%.
Sponsored
Invest with ease
From new investors to experts, Qtrade Direct Investing™ offers an intuitive experience with features including in-depth research and powerful tools.
Recognized by The Globe and Mail as a top-ranked broker for the 4th year in a row, you can count on Canada’s best online trading support for friendly and responsive client service and online self-help.
Get started today with no minimum investment and now get up to $150 sign-up bonus until June 30, 2023 with promo code BONUS150.
Division of Credential Qtrade Securities Inc.